HEALTHCARE ASSOCIATED INFECTION SURVEILLANCE IN THE ERA OF ELECTRONIC HEALTH DATA

Philip Russo, PhD, MClinEpid, BN

Associate Professor

Director, Cabrini Monash University Department of Nursing Research

Hosted by Jane Barnett jane@webbertraining.com

www.webbertraining.com

April 3, 2019

Objectives

- Provide brief historical background to HAI surveillance
- Discuss current surveillance issues, including findings of a systematic review the impact of electronic HAI surveillance software on IP's
- Explore future surveillance options in the era of electronic medical records


Background

Healthcare associated infection (HAI) is an

infection that occurs as a result of a healthcare intervention and may occur within, or after leaving, a healthcare facility. ¹

Surveillance

"ongoing and systematic collection, analysis and interpretation of outcome specific data essential to the planning, implementation, and evaluation of public health practice, closely integrated with the timely dissemination of these data to those who <u>need to know</u>"²




NHMRC 2010
 Thacker 1996

Why do HAI surveillance?

SENIC⁷

- a structured surveillance program
- one infection prevention nurse per 250 beds
- an infection prevention physician
- a system for reporting infection rates to surgeons




7. Haley et al. 1985 8. Wilson 2013 9. Damani 2012

Why do HAI surveillance?

SENIC⁷

• a structured surveillance program




SSI | BSI | UTI | VAP

7. Haley et al. 1985
 8. Wilson 2013
 9. Damani 2012

Why do HAI surveillance?

SENIC⁷

• a structured surveillance program





7. Haley et al. 1985
 8. Wilson 2013
 9. Damani 2012

Objectives 8,9

- Establish baseline/endemic rates
- Detect clustering/potential outbreaks
- Assess effectiveness of interventions
- Generate hypotheses/research
- Quality improvement
- Guide treatment and prevention strategies
- Meet regulatory requirements
- Benchmark
- Reduce the incidence of preventable infections

Data for Action

Infection prevention activities

product evaluations Collect HAI data deliver education patient education Collect audit data Assess education needs External data reporting IPC team meetings implement interventions interpret test results Interpret audit data communication with clinicians advice re precautions communication with clinicians sterilisingaccreditation preparation communication with management Develop education materials IC Committee meetings manage IC breaches emergency preparedness outbreak advice strategic planning MRO screening review external policies staff health

Fig. 1. Word Cloud of ICP activities. The size of the word is representative of the number of ICPs undertaking each activity.

Hall et al. IDH 2015

Infection prevention activities





Fig. 1. Word Cloud of ICP activities. The size of the word is representative of the number of ICPs undertaking each activity.

3. Hall et al. IDH 2015

ICP time spent on surveillance



23-38% use dedicated surveillance software 6-8

4. Mitchell et al IDH 2016
 5. Stone et al AJIC 2009
 6. Grota et al AJIC 2010
 7. Halpin et al AJIC 2011
 8. Masnick ICHE 2014

Common practices...

- HAI surveillance, manual data collection, medical record review, pathology, radiology, patient review
- Double data entry, error prone, slow turnaround
- National study of 92 IP nurses, agreement levels of HAI identification varied between 53-75%

Russo et al. AJIC 2015

Leading to HAI Data Quality issues...


- Misclassification of HAIs
 - misinterpretation of definitions
 - inconsistent methods
- Subjective elements = natural variation
- Influenced by surveillance intensity, available resources, skill and knowledge, use of electronic tools
- Performance measurement
 - Potential to manipulate data

Rich et al AJIC 2013

Hello Publicly reported HAI data

- Robust, captured consistently over time and validated ¹¹
- An association exists with increased quality improvement measures in hospitals¹²
- Implementation in Australia of financial penalties linked to HAI outcomes as an incentive to improve quality of care ¹³

11. Talbot et al. Ann Intern Med 2013
12. Humphreys et al. Clin Micro Inf 2008
13. Magid et al. Infection, Disease and Health 2017
12



Aim

• Describe the findings of a systematic review on the impact of electronic surveillance software (ESS) on infection prevention resources

Method

- Medline & CINAHL
- 1 January 2006 and 31 December 2016

Inclusion / Exclusion

- cohort studies, case–control studies, crosssectional studies, observational studies, randomised controlled trials or case reports of HAI
- refer to the impact of electronic surveillance software post implementation on infection control resources in a hospital

- all grey literature
- non-peer reviewed
- conference abstracts
- papers written in languages other than
 English
- reviews, editorials, commentaries or policy statements

Definitions

- Electronic surveillance software
 - a system that performs electronic healthcare associated infection surveillance or
 - an automated process that identifies healthcare associated infections
- Healthcare-associated infection
 - any infection as defined or accepted by the authors as being healthcare associated, hospital acquired or nosocomial
- Resources
 - staffing, models of staffing, infrastructure or delivery of infection control services




Table I
Overview of studies involving electronic surveillance systems and effect on infection control resources

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle— Ottowa score (risk of bias)
Mann <i>et al</i> . [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (<i>P</i> = 0.16)	100	100	5
Streefkerk <i>et al.</i> [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI, BSI other		In-house	11,460	180	98.4	91	NR	6
Wright <i>et al</i> . [26], USA	3	Prospective cohort	Device-days for device-related HCAI	ICU	Commercial	8760	240	97.3 (P < 0.01)	99	99	6
Brossette <i>et al</i> . [27], USA	3	Prospective cohort	All HCAIs	Hospital wide	Commercial	3600	120	96.7	86	98	5
Nuckchady <i>et al</i> . [28], USA	1	Retrospective cohort	iVAC	ICU	In-house	6000	360	94.0	95	99	5
Streefkerk <i>et al</i> . [29], Netherlands	1	Retrospective cohort	SSI, LRTI, UTI, BSI	Hospital- wide	In-house	12,000	1200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper <i>et al</i> . [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (P < 0.01)	93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs		Commercial survey tool	33	13	60.6 (P < 0.01)	NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01)	84	100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota <i>et al</i> . [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized or did not	960	840	12.5 (<i>P</i> = 0.32)	NR	NR	₄ 19

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle– Ottowa score (risk of bias)
Mann <i>et al</i> . [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (P = 0.16)	100	100	5
Streefkerk et al. [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI, BSI other		In-house	11,460	180	98.4	91	NR	6
Wright et al. [26], USA	3	Prospective cohort	Device-days for device-related HCAI	ICU	Commercial	8760	240	97.3 (P < 0.01)	99	99	6
Brossette <i>et al</i> . [27], USA	3	Prospective cohort	All HCAIs	Hospital wide	Commercial	3600	120	96.7	86	98	5
Nuckchady et al. [28], USA	1	Retrospective cohort	iVAC	ICU	In-house	6000	360	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective cohort	SSI, LRTI, UTI, BSI	Hospital- wide	In-house	12,000	1200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper <i>et al.</i> [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (P < 0.01)	93	88	5
Peterson <i>et al.</i> [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs	Paediatric ID post discharge	Commercial survey tool	33	13	60.6 (P < 0.01)	NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01)	84	100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota et al. [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized or did not specify	960	840	12.5 (<i>P</i> = 0.32)	NR	NR	4 20

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle- Ottowa score (risk of bias)
Mann <i>et al.</i> [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (<i>P</i> = 0.16)	100	100	5
Streefkerk <i>et al.</i> [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI, BSI other		In-house	11,460	180	98.4	91	NR	6
Wright et al. [26], USA	3	Prospective cohort	Device-days for device-related HCAI	ICU	Commercial	8760	240	97.3 (P < 0.01)	99	99	6
Brossette et al. [27], USA	3	Prospective cohort	All HCAIs	Hospital wide	Commercial	3600	120	96.7	86	98	5
Nuckchady <i>et al</i> . [28], USA	1	Retrospective cohort	iVAC	ICU	In-house	6000	360	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective cohort	SSI, LRTI, UTI, BSI	Hospital- wide	In-house	12,000	1200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper <i>et al</i> . [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (<i>P</i> < 0.01)	93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs	Paediatric ID post discharge	Commercial survey tool	33	13	60.6 (P < 0.01)	NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01)	84	100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota <i>et al</i> . [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized or did not specify	960	840	12.5 (<i>P</i> = 0.32)	NR	NR	4 21

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle- Ottowa score (risk of bias)
Mann <i>et al.</i> [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (<i>P</i> = 0.16)	100	100	5
Streefkerk <i>et al.</i> [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI, BSI other		In-house	11,460	180	98.4	91	NR	6
Wright et al. [26], USA	3	Prospective cohort	Device-days for device-related HCAI	ICU	Commercial	8760	240	97.3 (P < 0.01)	99	99	6
Brossette et al. [27], USA	3	Prospective cohort	All HCAIs	Hospital wide	Commercial	3600	120	96.7	86	98	5
Nuckchady <i>et al</i> . [28], USA	1	Retrospective cohort	iVAC	ICU	In-house	6000	360	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective cohort	SSI, LRTI, UTI, BSI	Hospital- wide	In-house	12,000	1200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper et al. [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (P < 0.01)	93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs	Paediatric ID post discharge	Commercial survey tool	33	13	60.6 (P < 0.01)	NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01)	84	100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota <i>et al</i> . [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized or did not specify	960	840	12.5 (<i>P</i> = 0.32)	NR	NR	4 22

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle– Ottowa score (risk of bias)
Mann <i>et al</i> . [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (P = 0.16)	100	100	5
Streefkerk et al. [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI, BSI other		In-house	11,460	180	98.4	91	NR	6
Wright et al. [26], USA	3	Prospective cohort	Device-days for device-related HCAI	ICU	Commercial	8760	240	97.3 (P < 0.01)	99	99	6
Brossette et al. [27], USA	3	Prospective cohort	All HCAIs	Hospital wide	Commercial	3600	120	96.7	86	98	5
Nuckchady <i>et al</i> . [28], USA	1	Retrospective cohort	iVAC	ICU	In-house	6000	360	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective cohort	SSI, LRTI, UTI, BSI	Hospital- wide	In-house	12,000	1200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper <i>et al</i> . [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (<i>P</i> < 0.01)	93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs	Paediatric ID post discharge	Commercial survey tool	33	13	60.6 (P < 0.01)	NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01)	84	100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota <i>et al</i> . [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized or did not specify	960	840	12.5 (<i>P</i> = 0.32)	NR	NR	4 23

Table I
Overview of studies involving electronic surveillance systems and effect on infection control resources

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle— Ottowa score (risk of bias)
Mann <i>et al</i> . [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (P = 0.16)	100	100	5
Streefkerk et al. [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI, BSI other		In-house	11,460	180	98.4	91	NR	6
Wright <i>et al</i> . [26], USA	3	Prospective cohort	Device-days for device-related HCAI	ICU	Commercial	8760	240	97.3 (P < 0.01)	99	99	6
Brossette et al. [27], USA	3	Prospective cohort	All HCAIs	Hospital wide	Commercial	3600	120	96.7	86	98	5
Nuckchady et al. [28], USA	1	Retrospective cohort	iVAC	ICU	In-house	6000	360	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective cohort	SSI, LRTI, UTI, BSI	Hospital- wide	In-house	12,000	1200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper <i>et al</i> . [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (P < 0.01)	93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs	Paediatric ID post discharge	Commercial survey tool	33	13	60.6 (P < 0.01)	NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01)	84	100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota <i>et al</i> . [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized	960	840	12.5 (<i>P</i> = 0.32)	NR	NR	4
		-			or did not specify						24

Table I Overview of studies in	volving elec	tronic surveillan	ce systems and	effect on inf	ection control r	esources	
Poforonco, country	No. of	Study docian	Types of	Clinical	Commorcial	Timo pro-	Time post-

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle— Ottowa score (risk of bias)
Mann <i>et al</i> . [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (P = 0.16)	100	100	5
Streefkerk et al. [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI. BSI other		In-house	11,460	180	98.4	91	NR	6
Wright <i>et al</i> . [26], USA	3	Prospective cohort					40	97.3 (P < 0.01)	99	99	6
Brossette et al. [27],	3	Prospective			collectio		20	96.7	86	98	5
USA Nuckchady <i>et al</i> . [28], USA	1	cohort Retrospective cohort	Ca	ise as	certainm	nent	60	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective	UTI, BSI	wide	e12, 17.		200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper <i>et al</i> . [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (P < 0.01)	93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs	Paediatric ID post discharge	Commercial survey tool	33	13	60.6 (P < 0.01)	NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	-	In-house	13,380	5400	59.6 (P < 0.01)	84	100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota <i>et al</i> . [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized	960	840	12.5 (<i>P</i> = 0.32)	NR	NR	4
		-			or did not specify						25

Table I	
Overview of studies involving electronic surveillance systems and effect on infection control resources	5

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time po ESS conve into minu	rted reduction	Sensitivity (%)	Specificity (%)	Newcastle— Ottowa score (risk of bias)
Mann <i>et al</i> . [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (P = 0.16) 100	100	5
Streefkerk et al. [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI. BSI other		In-house	11,460	180	98.4	91	NR	6
Wright <i>et al</i> . [26], USA	3	Prospective cohort					40	97.3 (P < 0.01) 99	99	6
Brossette <i>et al</i> . [27], USA	3	Prospective cohort	All repo	orted	reductior	in tim	e 20	96.7	86	98	5
Nuckchady <i>et al</i> . [28], USA	1	Retrospective cohort		10 50	/ 00 40	,	60	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective		12.5%	6 - 98.4%	0	200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort		(mon	n 72 00/		50	84.8	90	100	5
Knepper <i>et al</i> . [31], USA	1	Retrospective cohort		(mea	n 73.9%)	148	84.2 (P < 0.01) 93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective	disease?	wide		1.00	20	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental			Commercial survey tool	33	13	60.6 (P < 0.01) NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01) 84	100	4
o <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota et al. [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized or did not specify	960	840	12.5 (<i>P</i> = 0.32) NR	NR	₄ 26

Table I	
Overview of studies involving electronic surveillance systems and effect on infection control resources	

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle– Ottowa score (risk of bias)
Mann <i>et al</i> . [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (P = 0.16)	100	100	5
Streefkerk et al. [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI, BSI other		In-house	11,460	180	98.4	91	NR	6
Wright <i>et al</i> . [26], USA	3	Prospective cohort	Device-days for device-related HCAI	ICU	Commercial	8760	240	97.3 (P < 0.01)	99	99	6
Brossette <i>et al</i> . [27], USA	3	Prospective cohort	All HCAIs	Hospital wide	Commercial	3600	120	96.7	86	98	5
Nuckchady <i>et al</i> . [28], USA	1	Retrospective cohort	iVAC	ICU	In-house	6000	360	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective cohort	SSI, LRTI, UTI, BSI	Hospital- wide	In-house	12,000	1200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper <i>et al</i> . [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (P < 0.01)	93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs	Paediatric ID post discharge	Commercial survey tool	33	13	60.6 (P < 0.01)	NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01)	84	100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota <i>et al</i> . [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized	960	840	12.5 (P = 0.32)	NR	NR	4
		Survey OF IFS			or did not specify						27

Table I	
Overview of studies involving electronic surveillance systems and effect on infection control resource	s

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle- Ottowa score (risk of bias)
Mann <i>et al</i> . [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (P = 0.16)	100	100	5
Streefkerk et al. [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI, BSI other		In-house	11,460	180	98.4	91	NR	6
Wright <i>et al</i> . [26], USA	3	Prospective cohort	Device-days for device-related HCAI	ICU	Commercial	8760	240	97.3 (P < 0.01)		99	6
Brossette <i>et al</i> . [27], USA	3	Prospective cohort	All HCAIs	Hospital wide	Commercial	3600	120	96.7	86	98	5
Nuckchady <i>et al</i> . [28], USA	1	Retrospective cohort	iVAC	ICU	In-house	6000	360	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective cohort	SSI, LRTI, UTI, BSI	Hospital- wide	In-house	12,000	1200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper <i>et al</i> . [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (P < 0.01)	93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs	Paediatric ID post discharge	Commercial survey tool	33	13	60.6 (P < 0.01)		NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01)		100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota <i>et al</i> . [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized or did not specify	960	840	12.5 (<i>P</i> = 0.32)	NR	NR	4 28

Table I
Overview of studies involving electronic surveillance systems and effect on infection control resources

Reference, country	No. of hospitals	Study design	Types of HCAI-related event monitored	Clinical areas used	Commercial product or in-house	Time pre- ESS converted into minutes	Time post- ESS converted into minutes	Percentage reduction (P-value) ^a	Sensitivity (%)	Specificity (%)	Newcastle– Ottowa score (risk of bias)
Mann <i>et al</i> . [24], USA	4	Prospective cohort	VAC	128 ICUs	In-house	61	1	98.4 (<i>P</i> = 0.16)	100	100	5
Streefkerk et al. [25], Netherlands	1	Retrospective cohort	Pre: All HCAIs. Post: SSI, LRTI, UTI, BSI other		In-house	11,460	180	98.4	91	NR	6
Wright <i>et al</i> . [26], USA	3	Prospective cohort	Device-days for device-related HCAI	ICU	Commercial	8760	240	97.3 (P < 0.01)	99	99	6
Brossette <i>et al</i> . [27], USA	3	Prospective cohort	All HCAIs	Hospital wide	Commercial	3600	120	96.7	86	98	5
Nuckchady <i>et al</i> . [28], USA	1	Retrospective cohort	iVAC	ICU	In-house	6000	360	94.0	95	99	5
Streefkerk <i>et al.</i> [29], Netherlands	1	Retrospective cohort	SSI, LRTI, UTI, BSI	Hospital- wide	In-house	12,000	1200	90.0	NR	NR	5
Blacky <i>et al</i> . [30], Austria	1	Retrosepctive cohort	BSI, CRI, PN, UTI	$2 \times ICU$	In-house	4950	750	84.8	90	100	5
Knepper <i>et al</i> . [31], USA	1	Retrospective cohort	SSI (colon FX)	Hospital- wide	In-house	26,418	4148	84.2 (P < 0.01)	93	88	5
Peterson <i>et al</i> . [32], USA	3	Prospective cohort	MRSA clinical disease?	Hospital- wide	Commercial	480	120	75.0	NR	NR	6
Kinnula <i>et al</i> . [33], Finland	1	Quasi- experimental	Post-discharge HCAIs	Paediatric ID post discharge	Commercial survey tool	33	13	60.6 (P < 0.01)	NR	NR	5
Chalfine <i>et al</i> . [34], France	1	Prospective cohort	SSI	Hospital- wide	In-house	13,380	5400	59.6 (P < 0.01)	84	100	4
Lo <i>et al</i> . [35], Taiwan	1	Cohort	HAUTI	Hospital- wide	In-house	3	2	33.3	NR	NR	5
Grota <i>et al</i> . [17], USA	207	Cross-sectional survey of IPs	n/a	n/a	48% commercial, 52% customized	960	840	12.5 (<i>P</i> = 0.32)	NR	NR	4
					or did not specify						29

3 other studies

- "Workload reduction of 90%"
- "Reduction of 10 weeks of ICP time per year"
- "< 3 minutes per device day"

Limitations

- Post 2006
- Inability to identify roles of IC team (US Hosp Epidemiologist)
- Impact on resources limited to time
- Variation in study design limits comparability
- No studies where effect was primary outcome

In summary...Surveillance software / automation...

Significantly reduces time





Appropriate for public reporting

More research





Where is it all going?

What is the purpose of surveillance?

What is the purpose of surveillance?

What we measure depends on how we measure,

which should depend on *why we measure*

Simon Sineks' "Golden Circle"

Surveillance



One system?



Image credits Copyright:© JCorbettcartoon - http://www.redbubble.com/people/jcorbettcartoo

	Research	Hospital infection prevention/ drive improveme nt	National Surveillance	Public reporting & financial penalty
Clinical relevance				
Actionable				
Large scale standardisation (robust)				
Reliable over time				
Robust to financial incentives				
Timely				
Risk Adjustment				


Modified from van Mourik ECCMID 2016


Electronic and Automated surveillance


- Ensure consistent application of definitions
 - Eliminate subjectiveness
- Reduce burden of data collection
 - Significantly reduce time spent on surveillance
- Improved sensitivity
- Automated, tailored and dissemination reporting

Trends de Bruin JAMIA 2014

- Combining data sources improves accuracy (micro, pharmacy A&D)
- Pharmacy data in combination with other data sources show excellent sensitivity (reasonable specificity)
- Antimicrobial data improves sensitivity
 - subject to prescribing habits
- Diagnostic codes are weak indicators for HAI
- Billing codes demonstrate high variability and inaccuracy for HAIs
- Recent studies bias towards higher sensitivity at expense of specificity
 - i.e finding true infections, but also investigating false positives








- Traditional surveillance
 - Infection control team
 - review every procedure

- Algorithm
 - Microbiology
 - Procedure
 - Admissions and Discharge
 - Pharmacy



- Number of cases reviewed
 - Traditional surveillance 1637
 - Identified 30 deep SSI

- Number of cases reviewed
 - Traditional surveillance 1637
 - Identified 30 deep SSI

- Number of cases reviewed
 - Algorithm "High Risk" 40
 - Identified 30 deep SSI
 - Se 100% PPV 68%

- Number of cases reviewed
 - Traditional surveillance 1637
 - Identified 30 deep SSI

- Number of cases reviewed
 - Algorithm "High Risk" 40
 - Identified 30 deep SSI
 - Se 100% PPV 68%

97% reduction in medical records reviewed

Infection Control & Hospital Epidemiology (2019), 1–5 doi:10.1017/ice.2019.36



Original Article

A diagnostic algorithm for the surveillance of deep surgical site infections after colorectal surgery


Tessa Mulder MD¹ , Marjolein F.Q. Kluytmans-van den Bergh MD^{1,2,3}, Maaike S.M. van Mourik MD, PhD⁴, Jannie Romme³, Rogier M.P.H. Crolla MD⁵, Marc J.M. Bonten MD, PhD^{1,4} and Jan A.J.W. Kluytmans MD, PhD^{1,3}

- 1. Post op length of stay
- 2. Wound class
- 3. Readmission
- 4. Reoperation
- 5. 30 day mortality
- Reduced number of medical records to be reviewed by 63% (miss 2 deep SSI)

Semi automated Surveillance - SSI


Cho 2018 ICHE Korea

- >40,000 procedures, 38 surgical categories
- Se 96.7% | PPV 4.1%
- >60% decrease in time
- Procedure specific algorithms?



Fully automated Surveillance -BSI

Figure 4. Relative Ranking of 4 Medical Centers











Figure 4. Relative Ranking of 4 Medical Centers











Figure 4. Relative Ranking of 4 Medical Centers



Data quality - Administrative coding data

- Why use ACDs?
- ✓ convenient
- ✓ widespread
- ✓ electronic availability
- ✓ ease of use

Why Not?

X not developed for surveillance

X do not take into account clinical context

×poor discrimination between on admission Vs HA

Xtimeliness of coding

 \times variation in coding habit

Marra 2017 reported **Se 2%** using ICD 10 codes for CAUTI BUT may supplement other strategy

Surveillance driving improvement

• Hallam 2018

- Adopted Matching Michigan program
- Reduce CRBSI across Trust
- Clinician engagement and collaboration
- Monthly CVAD data "Dashboard"
 - Raw data, rates, days between infections
- Root cause analysis
- Continuous review, feedback and improvement
- Significant reduction CRBSI over 5 years: 5/1000 CDs V 0.23/1000 CDs

Hallam 2018 JIP

Surveillance driving improvement

- Standardisation care plans and pathways
- Clinician involvement
- Don't wait for the mandate!



Hallam 2018 JIP

Public reporting at surgeon level

- 4 years colorectal surgery 90 day mortality (DM)
- Pre and post public reporting of surgeon data
 - ✓ No difference in type of pts receiving surgery
 - ✓ No evidence of change in care
 - ✓ Significant decrease in 90 DM for elective procedures
 - ✓ No change in 90 DM for emergent procedures

Vallance 2018 BMJ

Public reporting at surgeon level

- No risk averse behaviour
- No gaming of data
- Suggest improvement in elective pts resulted from improved pre-operative processes
- Surgeon specific?
- Teams?
- Hospitals?

Vallance 2018 BMJ

Public reporting HAI data

What do consumers want to know?

- Semi structured interviews
- 20 electively admitted surgical inpatients
- Large acute hospital

Poor awareness of HAI, little or no pre op information

Russo 2019 AJIC

Public reporting HAI data

More focussed on their current illness

"I'm not really worried about a bloody infection, I'm just hoping they can start me heart up again"

Russo 2019 AJIC

Public reporting HAI data

Does not influence choice, loyalty more important

"I came here because they've got all my records here. I've been dealing with them for over 20 years and they're very, very good to me"

Russo 2019 AJIC

	Research	Hospital infection prevention/ drive improveme nt	National surveillance	Public reporting & financial penalty
Clinical relevance	\checkmark			
Actionable	\checkmark			
Large scale standardisation (robust)				
Reliable over time				
Robust to financial incentives				
Timely				
Risk Adjustment	\checkmark			

Modified from van Mourik ECCMID 2016

	Research	Hospital infection prevention/ drive improveme nt	National surveillance	Public reporting & financial penalty
Clinical relevance	\checkmark	\checkmark		
Actionable	\checkmark	\checkmark		
Large scale standardisation (robust)				
Reliable over time		\checkmark		
Robust to financial incentives				
Timely		\checkmark		
Risk Adjustment	\checkmark			

Modified from van Mourik ECCMID 2016

	Research	Hospital infection prevention/ drive improveme nt	National surveillance	Public reporting & financial penalty
Clinical relevance	\checkmark	\checkmark		
Actionable	\checkmark	\checkmark		
Large scale standardisation (robust)			\checkmark	
Reliable over time		\checkmark	\checkmark	
Robust to financial incentives				
Timely		\checkmark		
Risk Adjustment	\checkmark		\checkmark	

	Research	Hospital infection prevention/ drive improveme nt	National surveillance	Public reporting & financial penalty
Clinical relevance	\checkmark	\checkmark		
Actionable	\checkmark	\checkmark		
Large scale standardisation (robust)			\checkmark	\checkmark
Reliable over time		\checkmark	\checkmark	\checkmark
Robust to financial incentives				\checkmark
Timely		\checkmark		
Risk Adjustment	\checkmark		\checkmark	\checkmark

Modified from van Mourik ECCMID 2016

	Research	Hospital infection prevention/ drive improveme nt	National surveillance	Public reporting & financial penalty
Clinical relevance	\checkmark	\checkmark		
Actionable	\checkmark	\checkmark		\frown
arge scale standardisation (robust)			\checkmark	
liable over time		\checkmark	\checkmark	\checkmark
obust to financial incentives				
mely		\checkmark		\bigcirc
sk Adjustment	\checkmark		\checkmark	\checkmark

Concluding thoughts

- What is the role of the Infection Preventionist?
 - Semi automated make a final determination
 - Fully automated no involvement
- Is HAI data without some clinician determination acceptable?

Concluding thoughts

- Semi automated
 - local quality improvement / measure effect of interventions
- Fully automated
 - Large scale, mandated, public reporting

Questions?



	www.webbertraining.com/schedulep1.php
April 9, 2019	(FREE European Teleclass Denver Russell Memorial Teleclass Lecture) MODERN TOOLS FOR BACTERIAL IDENTIFICATION AND ANTIBIOTIC SUSCEPTIBILITY TESTING Speaker: Prof. Vincent Cattoir, Université de Caen Basse-Normandie, France
April 18, 2019	INFECTION CONTROL ISSUES IN HEALTHCARE CONSTRUCTION, PART 1 - RENOVATION Speaker: Andrew Streifel, University of Minnesota
May 2, 2019	(FREE Teleclass) POSTPONED TO LATER IN THE YEAR EMERGING DISEASES Speaker: Prof. Laura Kahn, Woodrow Wilson School of Public and International Affairs, Princeton University
May 3, 2019	(FREE WHO Teleclass - Europe) SPECIAL LECTURE FOR 5 MAY Speaker: Prof. Didier Pittet, World Health Organization, Geneva

Thanks to Teleclass Education PATRON SPONSORS

